FR24C1049I2 - Formulations liquides et lyophilisées stabilisées de adamts13 - Google Patents

Formulations liquides et lyophilisées stabilisées de adamts13

Info

Publication number
FR24C1049I2
FR24C1049I2 FR24C1049C FR24C1049C FR24C1049I2 FR 24C1049 I2 FR24C1049 I2 FR 24C1049I2 FR 24C1049 C FR24C1049 C FR 24C1049C FR 24C1049 C FR24C1049 C FR 24C1049C FR 24C1049 I2 FR24C1049 I2 FR 24C1049I2
Authority
FR
France
Prior art keywords
adamts13
freeze
stabilized liquid
dried formulations
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1049C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of FR24C1049I1 publication Critical patent/FR24C1049I1/fr
Application granted granted Critical
Publication of FR24C1049I2 publication Critical patent/FR24C1049I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR24C1049C 2009-09-21 2024-12-10 Formulations liquides et lyophilisées stabilisées de adamts13 Active FR24C1049I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24435309P 2009-09-21 2009-09-21
EP10759786.6A EP2480198B9 (en) 2009-09-21 2010-09-21 Stabilized liquid and lyophilized adamts13 formulations
PCT/US2010/049723 WO2011035335A2 (en) 2009-09-21 2010-09-21 Stabilized liquid and lyophilized adamts13 formulations
EP15203085.4A EP3167897B1 (en) 2009-09-21 2010-09-21 Stabilized liquid and lyophilized adamts13 formulations

Publications (2)

Publication Number Publication Date
FR24C1049I1 FR24C1049I1 (fr) 2025-01-17
FR24C1049I2 true FR24C1049I2 (fr) 2025-12-12

Family

ID=43598388

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1049C Active FR24C1049I2 (fr) 2009-09-21 2024-12-10 Formulations liquides et lyophilisées stabilisées de adamts13

Country Status (21)

Country Link
US (9) US8623352B2 (enExample)
EP (5) EP4467160A3 (enExample)
JP (2) JP5819303B2 (enExample)
KR (6) KR20210054598A (enExample)
CN (2) CN102573792B (enExample)
AU (1) AU2010295299B2 (enExample)
BR (1) BR112012006283B1 (enExample)
CA (1) CA2774556A1 (enExample)
DK (4) DK2480198T3 (enExample)
EA (1) EA024267B1 (enExample)
ES (4) ES2948612T3 (enExample)
FI (2) FI4218797T3 (enExample)
FR (1) FR24C1049I2 (enExample)
HR (1) HRP20160295T1 (enExample)
HU (1) HUE028688T2 (enExample)
IN (1) IN2012DN02645A (enExample)
MX (3) MX339205B (enExample)
NZ (1) NZ598839A (enExample)
PL (4) PL2480198T3 (enExample)
PT (2) PT3834841T (enExample)
WO (1) WO2011035335A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358895B1 (en) 2008-12-05 2018-05-30 Baxalta GmbH Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
US8623352B2 (en) 2009-09-21 2014-01-07 Baxter International Inc. Stabilized liquid and lyophilized ADAMTS13 formulations
EP3311847A1 (en) * 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
CN103566362B (zh) * 2012-07-21 2015-07-29 复旦大学 重组adamts13在制备脑出血药物中的用途
CA2890848C (en) * 2012-11-09 2020-11-17 Puget Sound Blood Center Protein stabilizing factors apolipoprotein a-1 or high density lipoprotein
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
WO2014145050A1 (en) 2013-03-15 2014-09-18 Atyr Pharma, Inc. Histidyl-trna synthetase-fc conjugates
MX377774B (es) * 2014-06-26 2025-03-11 Amgen Inc Formulaciones de proteinas.
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
EP3988938B1 (en) 2016-01-08 2024-06-12 Kyoto University Medicine comprising adamts13 as main ingredient
CA3031740A1 (en) 2016-08-04 2018-02-08 Baxalta Incorporated Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
PL3534922T3 (pl) 2016-11-04 2024-08-19 Takeda Pharmaceutical Company Limited Preparaty wirusa związanego z adenowirusem
WO2018195338A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
UA125971C2 (uk) * 2017-07-25 2022-07-20 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
US20210163990A1 (en) * 2018-07-11 2021-06-03 Baxalta Incorporated Aav compositions
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
MX2022012303A (es) 2020-04-02 2022-11-30 Takeda Pharmaceuticals Co Variante de adamts13, composiciones y usos de las mismas.
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
WO2022034595A1 (en) * 2020-08-13 2022-02-17 Hadasit Medical Research Services & Development Limited A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (adamts-13) mutants, compositions and therapeutic methods thereof
CN119173446A (zh) 2022-03-08 2024-12-20 赤盾医疗有限公司 机器人药物制备系统中的流体转移站
KR20240112755A (ko) * 2023-01-11 2024-07-19 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
PL198123B1 (pl) 1999-02-22 2008-05-30 Baxter Int Kompozycja czynnika VIII bez dodatku albuminy i jej zastosowanie
JP2001227510A (ja) 2000-02-15 2001-08-24 Tomoe Tech Res Co 複作動型の空気式アクチュエータ
JP3783507B2 (ja) 2000-02-16 2006-06-07 日本精工株式会社 トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
ITPR20010055A1 (it) 2001-08-31 2003-03-03 Vetroarredo Spa Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko) 2002-10-09 2005-03-10 동부아남반도체 주식회사 모스 트랜지스터 제조 방법
WO2005008241A1 (en) * 2003-07-07 2005-01-27 University Of North Carolina At Chapel Hill Method and system for detection of von willebrand factor (vwf) multimers
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PL1902141T3 (pl) 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
JP4880997B2 (ja) * 2005-12-28 2012-02-22 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の安定化方法
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
US8623352B2 (en) * 2009-09-21 2014-01-07 Baxter International Inc. Stabilized liquid and lyophilized ADAMTS13 formulations
US8823352B2 (en) 2011-07-11 2014-09-02 Linear Technology Corporation Switching power supply having separate AC and DC current sensing paths

Also Published As

Publication number Publication date
PL4218797T3 (pl) 2025-02-10
HUE028688T2 (en) 2017-01-30
WO2011035335A2 (en) 2011-03-24
KR20220139456A (ko) 2022-10-14
ES2865250T3 (es) 2021-10-15
EP4218797A1 (en) 2023-08-02
EP4467160A2 (en) 2024-11-27
MX2019000547A (es) 2020-11-12
EP4218797B1 (en) 2024-09-11
US20200376098A1 (en) 2020-12-03
EP3834841A1 (en) 2021-06-16
EP3167897B1 (en) 2021-01-27
EP2480198A2 (en) 2012-08-01
NZ598839A (en) 2014-03-28
US9351935B2 (en) 2016-05-31
US20180207245A1 (en) 2018-07-26
EP2480198B1 (en) 2016-03-09
PT3834841T (pt) 2023-06-19
US20250099559A1 (en) 2025-03-27
US12178861B2 (en) 2024-12-31
WO2011035335A3 (en) 2011-12-01
BR112012006283B1 (pt) 2022-03-15
HRP20160295T1 (hr) 2016-05-20
DK2480198T3 (en) 2016-03-29
DK4218797T3 (da) 2024-12-09
ES2579906T3 (es) 2016-08-17
US9937244B2 (en) 2018-04-10
JP5819303B2 (ja) 2015-11-24
FI3834841T3 (fi) 2023-06-05
KR20250008986A (ko) 2025-01-16
MX339205B (es) 2016-05-16
CN104224705A (zh) 2014-12-24
FR24C1049I1 (fr) 2025-01-17
US20190247475A1 (en) 2019-08-15
ES3001509T3 (en) 2025-03-05
EP4467160A3 (en) 2025-01-15
AU2010295299A1 (en) 2012-04-12
DK4218797T5 (da) 2025-07-21
KR20210054598A (ko) 2021-05-13
BR112012006283A2 (pt) 2016-05-31
KR20180095738A (ko) 2018-08-27
US10758599B2 (en) 2020-09-01
ES2948612T3 (es) 2023-09-14
DK3834841T3 (da) 2023-06-06
US20110229455A1 (en) 2011-09-22
EP2480198B9 (en) 2016-11-23
PL3834841T3 (pl) 2023-07-24
EA024267B1 (ru) 2016-09-30
HK1173968A1 (zh) 2013-05-31
DK3167897T3 (da) 2021-04-19
US11564979B2 (en) 2023-01-31
PL3167897T3 (pl) 2021-09-27
KR20190137954A (ko) 2019-12-11
MX362382B (es) 2019-01-14
CN102573792B (zh) 2014-10-15
EA201200519A1 (ru) 2012-09-28
EP3834841B1 (en) 2023-05-17
AU2010295299B2 (en) 2015-12-24
EP3167897A1 (en) 2017-05-17
JP2013505270A (ja) 2013-02-14
FI4218797T3 (fi) 2024-12-07
EP4218797B9 (en) 2025-03-05
MX2012003414A (es) 2012-06-19
JP2015063556A (ja) 2015-04-09
KR20120099646A (ko) 2012-09-11
US10238720B2 (en) 2019-03-26
CN102573792A (zh) 2012-07-11
US20140178357A1 (en) 2014-06-26
CA2774556A1 (en) 2011-03-24
PL2480198T3 (pl) 2016-09-30
IN2012DN02645A (enExample) 2015-09-11
PT4218797T (pt) 2024-12-09
US8623352B2 (en) 2014-01-07
CN104224705B (zh) 2018-02-02
US20230130866A1 (en) 2023-04-27
US20160375111A1 (en) 2016-12-29
KR101891646B1 (ko) 2018-08-27
US9572778B2 (en) 2017-02-21
US20170112906A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
FR24C1049I2 (fr) Formulations liquides et lyophilisées stabilisées de adamts13
ZA201107699B (en) Stable pharmaceutical composition and methods of using same
EP2632272A4 (en) BIOACTIVE CHROMACTERIAL COMPOSITIONS AND METABOLITES THEREOF
BR112013002845A2 (pt) combinação de susbtâncias ativas
BR112012014962A2 (pt) métodos e composições para formulações líquidas e estáveis de fármacos
BRPI1005960A2 (pt) sistema de implante e ultilização de um sistema de implante
EP2625624A4 (en) DISTRIBUTION OF CONTENTS AND BEHAVIOR TO DIFFERENT PLATFORMS
EP2515946A4 (en) NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES
EP2615912A4 (en) LIQUID AGRICULTURAL FORMULATIONS OF IMPROVED STABILITY
LT2805731T (lt) Stabilios polipeptidų kompozicijos ir jų panaudojimas
EP2600715A4 (en) ST-246 LIQUID FORMULATIONS AND METHOD THEREFOR
BRPI0908859A2 (pt) composição farmacêutica estabilizada de líquído único contedo docetaxel
IL219155A0 (en) Pharmaceutical formulations of nitrite and uses thereof
DK2391382T3 (da) Farmaceutisk præparat indeholdende lipase af bakteriel oprindelse
BRPI0818702A2 (pt) Formulação farmacêutica de ácido clavulânico
IL224191A (en) Compositions of vitamin d and cmc epi-14 analogues
IL213711A (en) Nano-phenofibrate preparation
IT1403064B1 (it) Composizione di sostanze per il trattamento di pazienti con ipercolesterolemia e patologie collegate
HK1152865A (en) Liquid and freeze dried formulations